Biosimilar Integration

CE / CME

Addressing Barriers to Biosimilar Integration in Cancer Care

Pharmacists : 0.25 contact {hour} ({0.025} CEUs)

Physicians : maximum of 0.25 AMA PRA Category 1 {Credit}

Released: December 18, 2018

Expiration: December 17, 2019

Gary Lyman
Gary Lyman, MD, MPH, FASCO, FRCP (Edin)

Activity

Progress
1
Course Completed

Although biologic therapies for cancer can dramatically improve outcomes for many patients, their high costs have resulted in somewhat tempered excitement. As patents on these products expire, biosimilars—biologic agents that are highly similar but not identical to an approved reference biologic—have begun to emerge as treatment options, increasing competition and potentially reducing the cost of biologic cancer therapies. Here, I discuss why some of the key reasons biosimilars may be more affordable could also pose challenges to their widespread adoption.

Biosimilars May Help to Curb Rising Healthcare Costs of Cancer Therapy
With the median monthly cost of treatment with new biologic cancer therapies exceeding

Poll

1.
How confident are you in prescribing a biosimilar instead of its reference biologic?
Submit